Related Experiment Video
Updated: Apr 27, 2026

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models
Published on: December 9, 2016
Recent development of RNAi in drug target discovery and validation
Guohong Liu1, Flossie Wong-Staal1, Qi-Xiang Li1
1Immusol Inc., 10790 Roselle Street, San Diego, CA 92121, United States.
Abstract:
This article reviews the recent development in two areas of RNAi technology that could potentially shorten the otherwise long process of drug development. First, the combinatorial gene silencing built on the RNAi library, particularly the coming of age of 'RNAi gene' libraries, by overcoming numerous technical hurdles and also increasing understanding of miRNA biogenesis, is gradually establishing more effective approaches to identifying drug targets. Second, regulated RNAi gene expression provides tools for in vivo target validation for both on-target efficacy and potential on-target toxicity.:
More Related Videos
Related Concept Videos
Experimental RNAi
RNA Interference
RNA Interference
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
Drug Discovery: Overview
Pharmacogenomics: Identification of New Drug Targets
siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...

